INR® 100 UCLA Medical Plaza, Suites 205-210 Los Angeles, California 90095 (310) 824-6199
Return to Home Page

Cambridge Healthtech Institute's 8th annual World Pharmaceutical Congress takes place in Philadelphia this year and will feature the inaugural Targeting Alzheimer's with Novel Therapeutics conference from June 10-11.

This inaugural Alzheimer's conference features the leading developers of cutting edge therapeutics for Alzheimer's disease, including perispinal etanercept, Rember™, and Dimebon™.

Edward Tobinick, M.D., Director of the INR® will present TNF Modulation for Treatment of Alzheimer's Disease, a discussion of the use of perispinal etanercept for Alzheimer's and related forms of dementia.

Claude M. Wischik, Ph.D., Professor Old Age Psychiatry University of Aberdeen and Chairman TauRx Therapeutics, will present Potential Efficacy of Tau Aggregation Inhibitor Therapy with Rember™ in Alzheimer's Disease and

Lynn Seely, M.D., Chief Medical Officer, Medivation, Inc. will present Dimebon: Turning an Old Drug to a New Use .

Rember™ and Dimebon™ are experimental drugs not presently available to the public for therapeutic use. Perispinal etanercept, a unique, patented[1] immunomodulatory approach developed by Dr. Tobinick at the INR®, is currently available to patients at the INR® Los Angeles and from INR trained physicians in North America, Europe and Africa.

Major pharmaceutical companies also searching for a treatment for the over 5 million Americans suffering from Alzheimer's disease will be represented at the Targeting Alzheimer's with Novel Therapeutics conference by:

Timothy A. Esbenshade, Ph.D., Senior Group Leader, Neuroscience Research, Abbott Laboratories

Scott D. Bembenek, Ph.D., Senior Scientist, Computer Aided Drug Discovery, Johnson & Johnson

Michael L. Hutton, Ph.D., Leader, Alzheimer's Group, Merck Research Laboratories

For further information, please visit:

World Pharmaceutical Congress website

<Map and Directions><Appointments><Terms of Use><Memory Disorders Program-detailed brochure (PDF)><Alzheimer treatment videos><Dementia><Citations to INR publications>
Copyright ©2009, the Institute for Neurological Research® (INR®), a private medical group, inc., all rights reserved. [1]U.S. patents 6,982,089 and 7,214,658, and additional issued and pending U.S. and foreign patents. These patents are assigned to TACT IP LLC. Please see the medical and legal disclaimer.

Perispinal etanercept for Alzheimer's disease and other forms of dementia is a patented, off-label treatment method developed at the INR®.